Fresenius Mabxience News and Resources

Fresenius Mabxience has announced a Contract Development and Manufacturing Organisation (CDMO) agreement with Biosidus. This collaboration aims to develop a treatment for Fabry disease, a rare genetic disorder. The use of Agalsidase Beta is an innovative treatment for Fabry disease. This